Relationship between Patients’ Baseline Characteristics and Survival Benefits in Immunotherapy-Treated Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis

Table 5

Differences in overall survival associated with immunotherapy in smoking status by subgroups.

		Participants, no.		Pooled HR (95% CI) for ICI vs. controlled therapies		Test for difference
Variable	Studies, no.	Smoker	Never smoker	Smoker	Never smoker	value
Overall	15	8679	1439	0.77 (0.71, 0.83)	0.85 (0.70, 1.03)	0.335
Line of therapy
First	10	5861	965	0.78 (0.71, 0.87)	0.80 (0.63, 1.01)	0.881
Subsequent	5	2818	474	0.74 (0.68, 0.82)	0.93 (0.60, 1.45)	0.334
Intervention therapy
ICI alone	10	5743	1020	0.75 (0.69, 0.83)	0.99 (0.81, 1.21)	0.019
ICI combined with non-ICI	5	2936	419	0.79 (0.70, 0.90)	0.67 (0.48, 0.92)	0.032
Pathologic types
Squamous	2	877	55	0.73 (0.50, 1.07)	0.85 (0.43, 1.68)	0.701
Nonsquamous	5	2767	482	0.76 (0.67, 0.86)	0.70 (0.50, 0.97)	0.626

Abbreviations: HR = hazard ratio; ICI= immune checkpoint inhibitor.